GLPwatch
The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
NCT03645408 · Terminated
Last updated 2026-05-28This clinical trial tests whether exenatide, a medication for diabetes, affects alcohol consumption in adults who drink heavily.
Status Terminated Stopped early and will not restart.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 8 people
Who can join Ages 21–55 · all sexes Healthy volunteers accepted.
Timeline Started 2019-05 · est. completion 2021-07
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT03645408 ↗
Description as written by the study sponsor.
A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol. The specific objective of this research was to determine whether exenatide has effects on alcohol consumption.
Treatments tested
- Exenatide also known as Byetta Drug
Subject received an injection of 5 mcg of immediate release exenatide.
- Sham injection also known as Placebo Other
Subjects received a sham injection with no study drug.
| Main thing measured | Alcohol Consumption |
|---|---|
| Sponsor | Boston Medical Center |
| Conditions studied | Alcohol Use Disorder |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03645408 ↗